Method for Personalized Diet Design

A kit for providing dietary advice to an individual comprising:

• a) a system for genotyping APOA5 locus for at least one polymorphic marker from a biological sample;
• and
• b) instructions that if one or two of alleles selected from the group consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C alleles is detected, the individual is advised to limit or avoid consumption of foods containing n-6 polyunsaturated fatty acids to avoid developing an atherogenic lipid profile, and that if no alleles selected from the group consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C or that the presence of a homozygous allele selected from the group consisting of APOA5−1131T, APOA5−3A, APOA5 IVS3+476G, and APOA5 1259T alleles is detected, the individual can consume n-6 polyunsaturated fatty acids without being at increased risk of developing an atherogenic lipid profile.

A kit for providing dietary advice to an individual comprising:

• a) a system for genotyping APOA5 locus for at least one polymorphic marker from a biological sample;
• and
• b) instructions that if one or two of alleles selected from the group consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C alleles is detected, the individual is advised to limit or avoid consumption of foods containing n-6 polyunsaturated fatty acids to avoid developing an atherogenic lipid profile.

A kit for providing dietary advice to an individual comprising:

• a) a system for genotyping APOA5 locus for at least one polymorphic marker from a biological sample;
• and
• b) instructions that if no alleles selected from the group consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C or that the presence of a homozygous allele selected from the group consisting of APOA5−1131T, APOA5−3A, APOA5 IVS3+476G, and APOA5 1259T alleles is detected, the individual can consume n-6 polyunsaturated fatty acids without being at increased risk of developing an atherogenic lipid profile.

A kit for screening for an individual at risk of atherogenic plasma lipid profile when exposed to polyunsaturated fatty acids, wherein the kit comprises a plurality of isolated oligonucleotides, the oligonucleotides corresponding to no more than about 100 polymorphisms, wherein at least one of the polymorphisms is selected from the group consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C, and a guideline that indicates that if any of the polymorphic alleles consisting of APOA5−1131C, APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C is detected in a biological sample from an individual, the individual should be advised to avoid n-6 polyunsaturated fatty acids.

A method for creating diet advice comprising:

• a) providing a service to create diet advice with a restricted amount of n-6 polyunsaturated fatty acids for an individual whose sample contains at least one allele selected from the group consisting of APOA5−113 IC5 APOA5−3G, APOA5 IVS3+476A, and APOA5 1259C;
• and
• b) delivering the diet advice to the individual.